AddThis

Taro receives FDA approval for Kytril generic

Related Content

No related items were found.

HAWTHORNE, N.Y. Taro Pharmaceutical Industries has received approval from the Food and Drug Administration to market its generic version of a drug used to prevent nausea and vomiting in patients on chemotherapy, the Israeli generic drug maker said Friday.

The FDA approved Taro’s granisetron hydrochloride tablets in the 1-mg strength. The tablets are a generic version of Roche’s Kytril tablets.

Granisetron tablets had sales of around $15 million in 2009, according to unnamed industry sources cited by Taro.

© 2014 Drug Store News. All Rights Reserved.